In this article Steve Lam, senior vice president and head of biologics, Patheon, looks at which choice is best when developing a biomanufacturing strategy.
Top choice
Global pharmaceutical companies are expanding their biologics pipeline, and biologics represent an increasingly large share of new drug approvals, accounting for 32% of total new molecular entities (NMEs) in 2016, up significantly from only 10% in 2005. There are currently 12,382 biologic projects in clinical development, 1,600 of them underway in neurology alone.